Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate

REFERENCES

• Ayala M. Estado actual del tratamiento de la leucemia mieloide crónica en México. Rev Hematol Mex. 2013;14:S5–S7.
   Google Scholar
• Aguayo A., Garcia-Alvarez E, Cazares-Ordonez Y, Crespo-Solis E, Martinez-Baños D, Guadarrama-Beltran E, et al. Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in Mexico City. Clin Leuk. 2008;2;261–266. doi:10.3816/CLK.2008.n.036
   Google Scholar
• Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480. doi:10.1056/NEJMoa020461
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood. 2012;120:1390–1397. doi:10.1182/blood-2012-03-378919
   PubMed Web of Science ®Google Scholar
• Matti BF, Alwan AF. Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study. Turk J Haematol. 2013;30:387–393. doi:10.4274/Tjh.2012.0135
   PubMedGoogle Scholar
• Aduwa E, Szydlo R, Marin D, Foroni L, Reid A, Goldman J, et al. Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. Blood. 2012;120:5087–5088. doi:10.1182/blood-2012-09-458463
   PubMed Web of Science ®Google Scholar
• Breccia M, Salaroli A, Serrao A, Zacheo I, Alimena G. Imatinib induces body mass changes in women with chronic myeloid leukemia. Ann Hematol. 2013;92:1581–1582. doi:10.1007/s00277-013-1752-y
   PubMed Web of Science ®Google Scholar
• Kyle UG, Piccoli A, Pichard C. Body composition measurements: interpretation finally made easy for clinical use. Curr Opin Clin Nutr Metab Care. 2003;6:387–393. doi:10.1097/01.mco.0000078988.18774.3d
   PubMedGoogle Scholar
• Espinosa-Cuevas M, Rivas-Rodríguez L, González-Medina EC, Atilano-Carsi X, Miranda-Alatriste P, Correa-Rotter R. Bioimpedance vector analysis for body composition in Mexican population. Rev Invest Clin 2007;59:15–24.
   PubMedGoogle Scholar
• Ávila-Rosas H, Caraveo-Enríquez VE, Valdés-Ramos R, Tejero-Barrera E. Evaluación del estado de nutrición. In: Casanueva E, Kaufer-Horwitz M, Pérez-Lizaur AB, Arroyo P, editors. Nutriología médica. 3rd ed. Mexico: Panamericana; 2008. pp. 748–783.
   Google Scholar
• Ravasco P, Anderson H, Mardones F. Métodos de valoración del estado nutricional. Nutr Hosp. 2010;3:57–66.
   Google Scholar
• Piccoli A, Pillon L, Dumler F. Impedance vector distribution by sex, race, body mass index, and age in the United States: standard reference intervals as bivariate Z scores. Nutrition. 2002;18:153–167. doi:10.1016/S0899-9007(01)00665-7
   PubMed Web of Science ®Google Scholar
• Kim, S.B., Lee, N.R., Shin, T.M. & Lee, Y.H. Development and evaluation of a multi-frequency bioelectrical impedance analysis analyzer for estimating acupoint composition. J Acupunct Meridian Stud. 2014;7:33–43. doi:10.1016/j.jams.2013.01.021
   PubMedGoogle Scholar
• Piccoli A, Rossi B, Pillon L, Bucciante G. A new method for monitoring body fluid variation by bioimpedance analysis: the RXc graph. Kidney Int. 1994;46:534–539. doi:10.1038/ki.1994.305
   PubMed Web of Science ®Google Scholar
• Lohman TG, Roche AF, Martorell R, editors. Anthropometric standardization reference manual. Champaign: Human Kinetics Books; 1988.
   Google Scholar
• WHO. Global database on body mass index BMI classification. Who Expert Consultation.
   Google Scholar
• Bioelectrical impedance analysis in body composition measurement: NIH Technology Assess Statement. 1994 Dec 12–14. Am J Clin Nutr. 1996;(Suppl.):524S–532S.
   PubMedGoogle Scholar
• Lukaski HC, Kyle UG, Kondrup J. Assessment of adult malnutrition and prognosis with bioelectrical impedance analysis: phase angle and impedance ratio. Curr Opin Clin Nutr Metab Care. 2017;20:330–339. doi:10.1097/MCO.0000000000000387
   PubMed Web of Science ®Google Scholar
• Piccoli A, Pastori G: BIVA software. Padova, Italy: Department of Medical and Surgical Sciences, University of Padova; 2002.
   Google Scholar
• Toso S, Piccoli A, Gusella M, Menon D, Crepaldi G, Bononi A, et al. Bioimpedance vector pattern in cancer patients without disease versus locally advanced or disseminated disease. Nutrition 2003;19:510–514. doi:10.1016/S0899-9007(02)01084-5
   PubMed Web of Science ®Google Scholar
• Rodríguez-García WD, García-Castañeda L, Orea-Tejeda A, Mendoza-Núñez V, González-Islas DG, Santillán-Díaz Cet al. Handgrip strength: reference values and its relationship with bioimpedance and anthropometric variables. Clin Nutr ESPEN. 2017;19:54–58. doi:10.1016/j.clnesp.2017.01.010
   Web of Science ®Google Scholar
• Piedras J, Reyes S, Cordoba S, Chavez R. Erythrocyte references values in a coulter S-Plus STKR in adult subjects living at 2240 meters above sea level. Rev Invest Clin. 1991;43:174–178.
   PubMedGoogle Scholar
• Baccarani M, Deininger MW, Rosti G, Hochhaus A, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122(6):872–884. Epub 2013 Jun 26. doi:10.1182/blood-2013-05-501569
   PubMedGoogle Scholar
• Ottery FD. Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol. 1995;22: 98–111.
   PubMed Web of Science ®Google Scholar
• Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, Romero-Martínez M, Hernández-Ávila M. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública; 2012.
   Google Scholar
• Evans W. Skeletal muscle loss: cachexia, sarcopenia and inactivity. Am J Clin Nutr. 2010;91(suppl):1123S–1127S. doi:10.3945/ajcn.2010.28608A
   PubMedGoogle Scholar
• Prado MMC, Baracos V, McCargar L, Mourtzakis M, Mulder K, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264–3268. doi:10.1158/1078-0432.CCR-06-3067
   PubMed Web of Science ®Google Scholar
• Moryoussef F, Dhooge M, Volet J, et al. Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J Cachexia Sarcopenia Muscle. 2015;6:343–350. doi:10.1002/jcsm.12047
   PubMedGoogle Scholar
• Huang P, Zhao X, Mattew F, Ransohoff R, Zhou L. Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J. 2009;23:2539–2548. doi:10.1096/fj.09-129833
   PubMed Web of Science ®Google Scholar